Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 4 | BMC Complementary Medicine and Therapies

Fig. 4

From: Phytochemical analysis and biological effects of Zingiber cassumunar extract and three phenylbutenoids: targeting NF-κB, Akt/MAPK, and caspase-3 pathways

Fig. 4

Inhibitory effects of three phenylbutenoids and PE on NO production and iNOS expression in LPS-induced inflammation in RAW264.7 macrophages. Secretion levels of NO following treatment with (A) compound D, (B) compound D acetate, (C) DMPBD, (D) PE, (E) western blot analysis showing iNOS protein bands in response to compound D, compound D acetate, DMPBD, and PE treatments, and (F) Relative expression of iNOS protein. All values are presented as the mean ± SEM from four independent experiments (n = 4). Different lowercase letters indicate significant differences between samples at p < 0.05, as determined by ANOVA followed by LSD post-hoc test. CD: (E)-1-(3,4-dimethoxyphenyl)but-3-en-1-ol (compound D), DA: (E)-1-(3,4-dimethoxyphenyl)but-3-en-1-yl acetate (compound D acetate), DMPBD: (E)-(3,4-dimethoxyphenyl)butadiene, PE: phenylbutenoid extract, Dex: dexamethasone, LPS: lipopolysaccharide

Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us